<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905525</url>
  </required_header>
  <id_info>
    <org_study_id>CCFZ533B2201</org_study_id>
    <nct_id>NCT03905525</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome</brief_title>
  <acronym>TWINSS</acronym>
  <official_title>A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjögren's Syndrome (TWINSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of
      multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, multicenter study of CFZ533 in 2
      distinct populations (cohorts) of patients with Sjögren's Syndrome: 1) moderate-to-severe
      disease (systemic and symptomatic involvement) and; 2) low systemic involvement but high
      symptom burden.

      The study includes up to 6 weeks screning period, 48 weeks of treatment (divided into
      treatment periods of 24 weeks each) and 12 weeks follow up. Study treament will be
      administered as bi-weekly subcutaneous injections.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 12, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be screened and enrolled into one of the 2 study Cohorts:
Cohort 1: At baseline subjects will be randomized in ratio 1:1:1:1 into one of three CFZ533 (iscalimab) arms (A, B or C) or to placebo (Arm D). After completion of 24 weeks of treatment (Period 1) placebo patients (Arm D) will be switched to active treatment (Arm D1) for the subsequent 24 weeks (Period 2).
Cohort 2: At baseline subjects will be randomized in ratio 1:1 to iscalimab (Arm E) or to placebo (Arm F). After completion of 24 weeks of treatment (Period 1), placebo patients (Arm F) will be switched to iscalimab active treatment (Arm F1) for the subsequent 24 weeks (Period 2).
All patients treated with iscalimab (Arms A,B,C,and E) in Period 1 will continue the same study treatment in Period 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Patients, investigator staff, persons performing the assessments, will remain blind to the identity of the treatment within each cohort from the time of randomization until end of the study visit (week 60)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) score from baseline at 24 weeks as compared to placebo</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 1 - Efficacy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EULAR Sjögren Syndrome Patient Reported Index (ESSPRI) score from baseline at 24 weeks as compared to placebo.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 2 - Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSPRI at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 1 - Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in score of Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) questionnaire at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 1&amp;2 - Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Physician Global Assessment (PhGA) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 1&amp;2 - Efficacy (Clinical Outcome Measures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ESSDAI at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 2 - Efficacy (Clinical Outcome Measures)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least 12 points improvement measured by score of Impact of Dry Eye on Everyday Life (IDEEL) questionnaire symptom bother module at Week 24.</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cohort 2 - Efficacy (Patient Reported Outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs), serious adverse events (SAEs) from baseline to Week 24 and from week 24 to the end of study</measure>
    <time_frame>60 weeks</time_frame>
    <description>Cohort 1&amp;2 - Safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Free Light Chain (FLC) levels at analysis visit up to end of study</measure>
    <time_frame>60 weeks</time_frame>
    <description>Cohort 1&amp;2 - Biomarkers (1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin IgG and IgM levels at analysis visits up to end of study</measure>
    <time_frame>60 weeks</time_frame>
    <description>Cohort 1&amp;2 - Biomarkers (2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in plasma CXCL-13 levels at analysis visits up to end of study</measure>
    <time_frame>60 weeks</time_frame>
    <description>Cohort 1&amp;2 - Biomarkers (3)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Sjögren Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort 1 /Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1/Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1/Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1/Arm D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose (up to week 24)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1/Arm D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 dose 1 (from week 24)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2/Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2/Arm F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dose (up to week 24)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cphort 2/Arm F1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CFZ533 dose 2 (from week 24)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CFZ533</intervention_name>
    <description>Biological</description>
    <arm_group_label>Cohort 1 /Arm A</arm_group_label>
    <arm_group_label>Cohort 1/Arm B</arm_group_label>
    <arm_group_label>Cohort 1/Arm C</arm_group_label>
    <arm_group_label>Cohort 1/Arm D1</arm_group_label>
    <arm_group_label>Cohort 2/Arm E</arm_group_label>
    <arm_group_label>Cphort 2/Arm F1</arm_group_label>
    <other_name>iscalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>liquid placebo for injections</description>
    <arm_group_label>Cohort 1/Arm D</arm_group_label>
    <arm_group_label>Cohort 2/Arm F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Male or female patient ≥ 18 years of age

          -  Classification of Sjögren's Syndrome according to ACR/EULAR 2016 criteria (Shiboski et
             al 2017)

          -  Seropositive for anti-Ro/SSA antibodies

          -  Stimulated whole salivary flow rate of ≥ 0.1 mL/min

        Inclusion criteria specific for Cohort 1:

          -  ESSDAI ≥ 5 within the 8 predefined organ domains

          -  ESSPRI score of ≥5

        Inclusion criteria specific for Cohort 2:

          -  ESSDAI &lt; 5 within 8 domains scored for inclusion criterion for Cohort 1

          -  ESSPRI fatigue subscore ≥ 5 or ESSPRI dryness subscore ≥ 5

        Exclusion Criteria:

          -  Sjögren's Syndrome overlap syndromes where another autoimmune rheumatic disease
             constitutes the principle illness

          -  Use of other investigational drugs

          -  Prior use of B cell depleting therapies, abatacept or any other immunosuppressants
             unless specifically allowe be the protocol.

          -  Use of steroids at dose &gt;10 mg/day.

          -  Uncontrolled ocular rosacea (affecting the eye adnexa), posterior blepharitis or
             Meibomian gland disease (this criterion applies only to patients considered for Cohort
             2)

          -  Active viral, bacterial or other infections requiring systemic treatment

          -  Receipt of live/attenuated vaccine within a 2-month period prior to randomization.

          -  Chronic infection with hepatitis B (HBV) or hepatitis C (HCV).

          -  Evidence of active tuberculosis (TB) infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <zip>30096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <state>Fejer</state>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>3339419</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>457 8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sasebo-city</city>
        <state>Nagasaki</state>
        <zip>857-1165</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ponte de Lima</city>
        <zip>4990 041</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orenburg</city>
        <zip>460000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>SI-1107</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06560</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuhuratbaba / Istanbul</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sjögren</keyword>
  <keyword>fatigue</keyword>
  <keyword>dryness</keyword>
  <keyword>anti-CD40</keyword>
  <keyword>CFZ533</keyword>
  <keyword>iscalimab</keyword>
  <keyword>TWINSS</keyword>
  <keyword>autoimmune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

